• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

D-手性肌醇及其在多囊卵巢综合征中的意义:系统评价。

D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review.

机构信息

Nottingham Medical School, University of Nottingham, Queens Medical Centre Campus Nottingham University Hospitals, Nottingham, NG7 2UH, United Kingdom.

出版信息

Gynecol Endocrinol. 2011 Apr;27(4):256-62. doi: 10.3109/09513590.2010.538099. Epub 2010 Dec 10.

DOI:10.3109/09513590.2010.538099
PMID:21142777
Abstract

BACKGROUND

The pathogenesis of polycystic ovary syndrome (PCOS) has been linked to the development of insulin resistance and hyperinsulinemia. The objective of this study is to investigate the effects of insulin sensitising agents such as D-chiro-inositol (DCI) on ovulation and insulin resistance in women with PCOS.

METHODS

This was a systematic review done in an Academic Department of Obstetrics and Gynaecology in the UK of all studies published on PCOS and DCI up till May 2010. Patients were women with PCOS receiving DCI or where the relationship between insulin resistance and DCI had been investigated. Ovulation rates and changes in insulin sensitivity were the main outcome measures.

RESULTS

Less DCI-IPG was released in PCOS women compared to controls and this seems to correlate positively with insulin resistance and hyperinsulinemia evident in these patients. DCI administration had beneficial effects on ovulation, anthropometric and metabolic markers in PCOS women by enhancing insulin. The effects of metformin in improving insulin action in PCOS women was achieved though the release of DCI-IPG mediators.

CONCLUSIONS

Heterogeneity observed in the methodologies of each study, the scarcity of relevant studies and the small sample sizes used prohibit reliable conclusions to be drawn. Therefore, more studies must be conducted in the future to evaluate accurately the effects of DCI in PCOS.

摘要

背景

多囊卵巢综合征(PCOS)的发病机制与胰岛素抵抗和高胰岛素血症的发展有关。本研究的目的是研究胰岛素增敏剂如 D-手性肌醇(DCI)对 PCOS 妇女排卵和胰岛素抵抗的影响。

方法

这是在英国一家妇产科学术部门对截至 2010 年 5 月发表的所有关于 PCOS 和 DCI 的研究进行的系统评价。患者为接受 DCI 治疗的 PCOS 妇女,或研究胰岛素抵抗与 DCI 之间关系的妇女。排卵率和胰岛素敏感性变化是主要的观察指标。

结果

与对照组相比,PCOS 妇女释放的 DCI-IPG 较少,这似乎与这些患者中明显的胰岛素抵抗和高胰岛素血症呈正相关。DCI 给药通过增强胰岛素对 PCOS 妇女的排卵、人体测量和代谢标志物具有有益的影响。二甲双胍通过释放 DCI-IPG 介导物来改善 PCOS 妇女的胰岛素作用。

结论

由于每个研究的方法学存在异质性、相关研究的稀缺性以及使用的小样本量,因此无法得出可靠的结论。因此,未来必须进行更多的研究,以准确评估 DCI 在 PCOS 中的作用。

相似文献

1
D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review.D-手性肌醇及其在多囊卵巢综合征中的意义:系统评价。
Gynecol Endocrinol. 2011 Apr;27(4):256-62. doi: 10.3109/09513590.2010.538099. Epub 2010 Dec 10.
2
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.用于患有多囊卵巢综合征、月经过少和生育力低下的女性的胰岛素增敏药物(二甲双胍、罗格列酮、吡格列酮、D-手性肌醇)。
Cochrane Database Syst Rev. 2017 Nov 29;11(11):CD003053. doi: 10.1002/14651858.CD003053.pub6.
3
Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome.用于多囊卵巢综合征的胰岛素增敏药物(二甲双胍、曲格列酮、罗格列酮、吡格列酮、D-手性肌醇)
Cochrane Database Syst Rev. 2003(3):CD003053. doi: 10.1002/14651858.CD003053.
4
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.用于患有多囊卵巢综合征、月经过少和生育力低下的女性的胰岛素增敏药物(二甲双胍、罗格列酮、吡格列酮、D-手性肌醇)
Cochrane Database Syst Rev. 2010 Jan 20(1):CD003053. doi: 10.1002/14651858.CD003053.pub4.
5
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.用于患有多囊卵巢综合征、月经过少和生育力低下的女性的胰岛素增敏药物(二甲双胍、罗格列酮、吡格列酮、D-手性肌醇)
Cochrane Database Syst Rev. 2012 May 16(5):CD003053. doi: 10.1002/14651858.CD003053.pub5.
6
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.用于患有多囊卵巢综合征、月经过少和生育力低下的女性的胰岛素增敏药物(二甲双胍、罗格列酮、吡格列酮、D-手性肌醇)
Cochrane Database Syst Rev. 2009 Oct 7(4):CD003053. doi: 10.1002/14651858.CD003053.pub3.
7
WITHDRAWN: Insulin-sensitising drugs for polycystic ovary syndrome.撤回:用于多囊卵巢综合征的胰岛素增敏药物。
Cochrane Database Syst Rev. 2009 Jul 8(3):CD003053. doi: 10.1002/14651858.CD003053.pub2.
8
Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome.腹腔镜下使用透热法或激光打孔以诱导无排卵性多囊卵巢综合征患者排卵。
Cochrane Database Syst Rev. 2012 Jun 13(6):CD001122. doi: 10.1002/14651858.CD001122.pub4.
9
Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies.多囊卵巢综合征中的胰岛素抵抗:正常血糖-高胰岛素钳夹研究的系统评价和荟萃分析
Hum Reprod. 2016 Nov;31(11):2619-2631. doi: 10.1093/humrep/dew243. Epub 2016 Oct 7.
10
Does metformin improve reproduction outcomes for non-obese, infertile women with polycystic ovary syndrome? Meta-analysis and systematic review.二甲双胍是否能改善非肥胖型多囊卵巢综合征不孕妇女的生殖结局?荟萃分析和系统评价。
Eur J Obstet Gynecol Reprod Biol. 2022 Apr;271:38-62. doi: 10.1016/j.ejogrb.2022.01.025. Epub 2022 Feb 1.

引用本文的文献

1
From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management.多囊卵巢综合征女性从糖尿病前期到2型糖尿病:生活方式与药物治疗
Int J Endocrinol. 2020 Jun 8;2020:6276187. doi: 10.1155/2020/6276187. eCollection 2020.
2
Inositol Pyrophosphate Pathways and Mechanisms: What Can We Learn from Plants?肌醇六磷酸途径和机制:我们能从植物中学到什么?
Molecules. 2020 Jun 17;25(12):2789. doi: 10.3390/molecules25122789.
3
Inositols' Importance in the Improvement of the Endocrine-Metabolic Profile in PCOS.
肌醇在多囊卵巢综合征患者内分泌代谢特征改善中的重要性。
Int J Mol Sci. 2019 Nov 18;20(22):5787. doi: 10.3390/ijms20225787.
4
Inositol for subfertile women with polycystic ovary syndrome.多囊卵巢综合征不孕女性使用肌醇的情况。
Cochrane Database Syst Rev. 2018 Dec 20;12(12):CD012378. doi: 10.1002/14651858.CD012378.pub2.
5
Nutrients as novel therapeutic approaches for metabolic disturbances in polycystic ovary syndrome.营养物质作为多囊卵巢综合征代谢紊乱的新型治疗方法。
EXCLI J. 2016 Sep 5;15:551-564. doi: 10.17179/excli2016-422. eCollection 2016.
6
Different Effects of Myoinositol plus Folic Acid versus Combined Oral Treatment on Androgen Levels in PCOS Women.肌醇加叶酸与联合口服治疗对多囊卵巢综合征女性雄激素水平的不同影响
Int J Endocrinol. 2016;2016:3206872. doi: 10.1155/2016/3206872. Epub 2016 Nov 2.
7
The inositols and polycystic ovary syndrome.肌醇与多囊卵巢综合征
Indian J Endocrinol Metab. 2016 Sep-Oct;20(5):720-724. doi: 10.4103/2230-8210.189231.
8
Poly Cystic Ovarian Syndrome: An Updated Overview.多囊卵巢综合征:最新综述
Front Physiol. 2016 Apr 5;7:124. doi: 10.3389/fphys.2016.00124. eCollection 2016.
9
The "Other" Inositols and Their Phosphates: Synthesis, Biology, and Medicine (with Recent Advances in myo-Inositol Chemistry).“其他”肌醇及其磷酸盐:合成、生物学与医学(含肌醇化学的最新进展)
Angew Chem Int Ed Engl. 2016 Jan 26;55(5):1614-50. doi: 10.1002/anie.201502227. Epub 2015 Dec 22.
10
History of infertility and risk of type 2 diabetes mellitus: a prospective cohort study.不孕症病史与2型糖尿病风险:一项前瞻性队列研究。
Diabetologia. 2015 Apr;58(4):707-15. doi: 10.1007/s00125-015-3493-z. Epub 2015 Jan 18.